trending Market Intelligence /marketintelligence/en/news-insights/trending/7HaTaxJt3qkQeMZhrGHM7A2 content esgSubNav
In This List

Regeneron halts development of respiratory treatment for infants

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Regeneron halts development of respiratory treatment for infants

Regeneron Pharmaceuticals Inc.'s suptavumab failed to meet its primary endpoint of preventing respiratory syncytial virus infections in preterm infants in a phase 3 study.

The infection known as RSV is a common virus that leads to cold-like symptoms in adults but can be more serious in young infants. Suptavumab is an antibody to RSV.

Regeneron plans to discontinue further clinical development for the treatment, the company said in a news release.